Top Injectable Manufacturer in Syria – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 3 hours ago
- 15 min read
Last Updated: July 25, 2026
TL;DR: Syria is the most changed pharmaceutical market in the Middle East. Since the transition of December 2024 the United States has terminated its Syria sanctions programme by Executive Order 14312 with effect from 1 July 2025, removed the Syrian Sanctions Regulations from the Code of Federal Regulations in August 2025 and repealed the Caesar Act outright on 18 December 2025; the European Union lifted all economic sanctions on 28 May 2025 and restored the EU–Syria Cooperation Agreement on 11 May 2026. Syria is no longer a comprehensively sanctioned jurisdiction, and for an Indian manufacturer the binding constraint is now banking execution and registration, not permission. The opportunity is concentrated and documented: the Ministry of Health held only about 20% of the required supply of certain cancer medicines as of April 2026 with other lines completely depleted, a trastuzumab tender attracted no bidder in January 2026, and the Ministry's own published oncology-import decision names India as one of six approved source countries with a three-document fast track. Registration runs through the Directorate of Pharmaceutical Affairs under Regulatory Decision No. 3/T of 19 February 2025 — a CTD dossier, a five-year registration certificate, a mandatory locally licensed warehouse or scientific office as agent, and a cap allowing an imported product only where fewer than three locally licensed and marketed equivalents exist. Two facts make Syria unusually favourable for a sterile injectables maker: hospital-administered injectables and anaesthetics are exempt from the Arabic package-insert requirement, and Syria's stability condition is Zone II at 25°C/60% RH — less demanding than India's own 30°C/70% RH. Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, exports to over 30 countries, and supports Syrian partners with CTD dossiers, consular-legalised documentation and English-language artwork.
Key Takeaways
Sanctions are no longer the obstacle — say it precisely, with dates. Executive Order 14312 of 30 June 2025 revoked the US Syria sanctions programme with effect from 1 July 2025; OFAC removed the Syrian Sanctions Regulations at 31 C.F.R. part 542 from the Code of Federal Regulations in August 2025; and the Caesar Syria Civilian Protection Act was repealed by section 6211 of the FY2026 National Defense Authorization Act on 18 December 2025, ending the threat of mandatory secondary sanctions. The EU adopted the legal acts lifting all economic sanctions on 28 May 2025, restored full application of the EU–Syria Cooperation Agreement on 11 May 2026, and on 18 May 2026 renewed only its targeted measures against former-regime individuals and entities. The UK revoked its sectoral, trade, financial and energy measures with effect from 25 April 2025. What remains is targeted: designations under the US PAARSS programme and EU and UK listings covering former-regime figures, human-rights abusers, captagon networks and Iran-linked entities. Screen counterparties; do not assume prohibition.
The import rule is a three-equivalents cap, not a blanket ban — and that distinction is the entire commercial strategy. Regulatory Decision No. 3/T of 19 February 2025, Art. 3.2.2(a), permits an application to register an imported medicine only where three locally licensed and marketed equivalents do not exist, an equivalent being matched on active substances, strength, pharmaceutical form and route of administration. A difference in any one of those four means the local product does not count. For sterile injectables, specific presentations — a particular vial strength, a lyophilised rather than liquid form, a specific route — frequently have zero or one local equivalent even where the molecule is made in Syria. Portfolio selection at strength-and-presentation level is therefore the whole exercise. A separate rule bars registering a licensor's own product where a local plant makes it under licence from that company.
Oncology is the clearest lane, and the Ministry's published decision names India by name. Regulatory Decision No. 14/T, still published on the Ministry of Health's live legislation portal, provides that for imported cancer medicines from the Russian Federation, China, India, Cuba, Belarus and Iran only three documents are required: a duly legalised Certificate of Pharmaceutical Product proving registration in the country of origin, accompanied by a sample identical to the product to be imported; a duly legalised GMP certificate for the manufacturing plant; and a document showing one year has elapsed since the product came into use in the country of origin. That collapses the ordinary burden of full CTD Modules 1–5, three years of origin-market history, three foreign registration certificates and a PSUR. Because Decision 14/T predates the transition, confirm current applicability with the Directorate of Pharmaceutical Affairs before relying on it — but the demand side is not in doubt: about 20% of required cancer-medicine supply held in April 2026, and customs pre-clearance priority for cancer medicines since January 2026.
Two structural advantages for an injectables maker that almost nobody writes about. First, labelling: Decision 3/T requires package inserts in Arabic as well as English, except where the product is an anaesthetic or an injectable administered in hospitals or health centres — in which case English alone suffices, provided a bilingual Arabic-and-English administration brochure accompanies every shipment. That removes the largest artwork and translation cost that normally makes small Middle East launch volumes uneconomic. Second, stability: WHO's country table records Syria at Zone II, 25°C/60% RH, communicated by the national authority, whereas India's own condition is 30°C/70% RH. An Indian manufacturer's existing package already over-covers Syria — the reverse of the position in almost every other Middle East market.
Introduction: Why an Injectable Manufacturer in Syria Must Meet Global Standards
Syria's health system serves a population usually put at roughly 23 to 25 million — no reliable census has been taken since 2004, and UN agencies use different denominators — of whom 15.6 million were assessed as requiring humanitarian assistance in May 2026. It is a system rebuilding under load. The HeRAMS 2025 round, reported in the 2026 Humanitarian Needs and Response Plan, found 57% of hospitals and 30% of primary health care centres fully functional, with more than 40% of facilities partially or non-functional for want of staff, equipment, medicines or utilities; the Health Minister has put the emigration of highly qualified medical personnel at 35%. At the same time the addressable market is expanding rather than contracting: some 1.67 million refugees and 1.92 million internally displaced people had returned since December 2024 as of May 2026, more than twenty war-damaged hospitals are under a rehabilitation plan, and an agreement in early 2026 brought north-east health cadres in Deir ez-Zor, Raqqa and Hasakah onto the Ministry of Health payroll, administratively unifying facilities that had operated outside the national system for years. Meanwhile the humanitarian channel is shrinking — health-sector funding coverage fell from around 19% in 2025 to 11–14% in early 2026 — while the Ministry channel and the private out-of-pocket market grow. That reallocation matters commercially: 91% of respondents report paying for health services, and pharmacies are increasingly the first point of care.
The demand behind that structure is specific enough to plan a portfolio around. Oncology is the best-documented shortage in the country: GLOBOCAN 2024 records 27,280 new cancer cases and 16,455 deaths a year, the Albairouni University Hospital complex treats around 60% of all Syrian cancer patients with roughly 1,000 patients a day across 500 beds and 300 chemotherapy day-chairs, and in April 2026 the National Advisory Committee for Blood and Oncology stated that the Ministry held only about 20% of the actual required supply for certain cancer medicines while stocks of other types were completely depleted — a gap made vivid by a trastuzumab tender that attracted no bidder in January 2026. Trauma is the second pillar: Syria recorded 1,602 mine and explosive-remnant casualties in 2025, the highest of any country in the world, and 2,172 casualties in the seventeen months from December 2024, driving demand for anaesthetics, analgesics, antibiotics, tranexamic acid, resuscitation drugs and intravenous fluids. Then dialysis, with 6,222 haemodialysis patients recorded across 116 facilities in a Ministry survey of November 2025 and machine numbers rising quickly; obstetric emergencies, with 13,700 births taking place without a skilled attendant in September and October 2025 alone; non-communicable disease, which the Ministry's 2026–2028 strategic plan puts at around 70% of mortality against 58% of communities reporting NCD medicines unavailable; and cutaneous leishmaniasis, with about 25,000 cases in 2025 and more than 13,000 in the first four months of 2026. Syria needs reliable imported sterile injectables from manufacturers whose quality systems will survive scrutiny.
What Sets a World-Class Injectable Manufacturer in Syria Apart
The first differentiator is genuine sterile-manufacturing capability rather than a general plant with a filling line bolted on. Sterile injectables bypass every natural barrier the body has, so sterility assurance cannot be inferred from a finished-product test alone — it has to be designed into the facility. Farbe Firma's operation in Gujarat, India is built around ISO Class 5 aseptic filling zones within classified surrounding areas, unidirectional personnel and material flows, validated terminal sterilisation or aseptic processing according to the molecule, routine media-fill validation, environmental and personnel monitoring with trended data, and Water-for-Injection generation and distribution held under continuous control. In Syria that architecture is tested twice: Decision 3/T requires a duly legalised GMP certificate for the finished-product plant and, separately, a duly legalised GMP certificate for the active-substance manufacturing site, and it requires samples for laboratory analysis in the Ministry of Health's own laboratories matching the submitted CTD, with an analysis file containing Module 3. Enforcement is active and visible: in July 2026 the Ministry withdrew and destroyed a locally made intravenous paracetamol 1,000 mg/100 mL and an azithromycin product released without the required approvals, with the Deputy Minister stating that early release without approvals leads to withdrawal and destruction even where the medicine is of good quality. Notably, that drive targets unregistered release rather than imports — a properly registered WHO-GMP import sits on the right side of it.
The second differentiator is market-access support built around Syria's actual pathway, including the parts that are inconvenient. Registration sits inside the Ministry of Health rather than in a separate agency: the Directorate of Pharmaceutical Affairs grants licensing and market-release approvals for locally manufactured and imported preparations, the Directorate of Drug Control and Pharmaceutical Research runs GMP inspection, laboratory analysis and pharmacovigilance, and the Directorate of Records and Licences licenses the warehouses and scientific offices, all under the Deputy Minister of Health for Pharmaceutical Affairs. A Syrian Medicines Authority is in preparation — a modernisation roadmap targeting WHO Maturity Level 3 was launched on 16 July 2026 with WHO, UNDP and QUAMED, modelled on the Jordan Food and Drug Administration — but it does not yet exist, and arriving before the regulator hardens is itself an argument for moving now. The governing instrument for medicines is Regulatory Decision No. 3/T of 19 February 2025, under Legislative Decree No. 24 of 2010; note that the English-language coverage of a Decision No. 4 of 2026 concerns supplements, foods and cosmetics rather than human medicines. Under Decision 3/T a registration certificate runs five years, renewal may be filed from six months before expiry with a further six-month grace, and a company that did not actually import during the five years is treated as filing afresh. There is no direct route: the marketing authorisation holder must itself be registered with the Ministry, must appoint a Ministry-licensed drug warehouse or scientific office under a duly legalised authorisation naming the delegated tasks, and the distribution chain is legally closed from manufacturer to licensed warehouse to pharmacy or hospital.
Quality Systems Behind Every Batch We Ship to Syria
Every Farbe Firma injectable batch destined for Syria is released only after the full analytical stack is complete and reviewed. Identity, assay and related substances are determined by HPLC and, where the monograph requires it, GC. Sterility and bacterial endotoxin testing by LAL are performed on every batch, with container-closure integrity and particulate matter assessed against compendial limits, and water content by Karl Fischer titration where the dosage form demands it. Methods are validated to ICH expectations and specifications are set against USP, BP, IP or EP as the market and customer require, with the pharmacopoeial basis stated on the certificate of analysis rather than left implicit. Two Syria-specific screens run alongside the standard release: Decision 3/T excludes products containing porcine derivatives outright — which means screening porcine heparin, porcine-derived gelatin, porcine stearates and porcine trypsin in biological processes rather than treating it as a labelling matter — and requires duly legalised declarations that materials of animal origin are free of TSE and BSE.
Behind release testing sits the quality architecture that makes those results meaningful. Stability programmes run on three batches under real-time conditions per ICH Q1A, with photostability per ICH Q1B where the molecule warrants it. Syria is one of the few markets in the region where an Indian manufacturer's existing package is more than sufficient rather than borderline: WHO's table of stability conditions for Member States records Syria in Climatic Zone II at 25°C ± 2°C / 60% RH ± 5%, communicated by the national regulatory authority, while India's own condition is 30°C/70% RH — more demanding on both temperature and humidity. We are candid about the nuance, though. The regulatory condition is 25°C/60% RH, but the supply-chain reality in interior Syria is far harsher, with unreliable electricity and cold-chain gaps, so for anything requiring 2–8°C the binding constraint is in-country transport and storage rather than the stability protocol; and because Decision 3/T treats any change to storage period or conditions as a formal variation, an overstated storage claim becomes a compliance problem rather than merely a quality one. Change control, deviation management, CAPA, supplier qualification and annual product quality review operate as a connected system rather than as separate files, batch records are retained so that any vial can be reconstructed from raw material to release years later, and the site is maintained in a state of continuous inspection readiness.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Syria for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, oncology support, anaesthesia and analgesia, cardiovascular and critical-care molecules, obstetric medicines, vitamins and parenteral-nutrition adjuncts, delivered as liquid vials, ampoules, lyophilised presentations and small-volume parenterals — which is precisely the shape of Syria's documented gap. Oncology and supportive-care injectables answer a supply position the Ministry itself put at about 20% of requirement in April 2026; anaesthesia, analgesia, antibiotics, tranexamic acid and resuscitation injectables answer 1,602 mine casualties in 2025 and 555,000 trauma consultations delivered by WHO in the same year; heparin, iron and erythropoietin answer 6,222 dialysis patients across 116 facilities; oxytocin and magnesium sulphate answer 13,700 unattended births in two months. For a Syrian warehouse assembling a hospital portfolio, or a scientific office building a registration pipeline, that breadth means one audited manufacturing partner, one documentation standard and one point of accountability rather than a patchwork of sources with uneven paperwork.
Our CDMO services scale from a single warehouse's launch portfolio to full tender volumes. Contract and third-party manufacturing runs under the customer's brand with technology transfer, analytical method transfer, stability commitment and regulatory documentation handled as one package. We prepare the CTD dossier to ICH Modules 1–5 with the Syria-specific Module 1, provide the consular-legalised Certificate of Pharmaceutical Product or Free Sale Certificate together with legalised GMP certificates for both the finished-product plant and the active-substance site and the manufacturing licence, prepare English artwork and the bilingual Arabic-and-English administration brochure that the hospital-injectable exemption requires with every shipment, and supply the batch-level certificates of analysis and retention-sample discipline a licensed warehouse needs to defend a product line. We also plan the portfolio around Decision 3/T's own mechanics rather than against them: because ampoule and liquid-vial presentations are treated as one pharmaceutical form, adding the second where the formulation is identical is handled as a pack addition rather than a new registration — cheaper and faster — while any change to the qualitative composition of actives requires full re-registration, and adding an injectable pack of different fill volume triggers fresh laboratory analysis.
Buyers stay with Farbe Firma because we are straightforward about what the Syrian route actually involves. The marketing authorisation holder must be registered with the Ministry before any product application, a Ministry-licensed warehouse or scientific office must hold a duly legalised authorisation naming the delegated tasks, import invoices are endorsed in favour of that licensed warehouse, and the imported product must be physically stamped with the phrase indicating it is imported specially for the account of the named warehouse — a marking requirement that belongs in artwork planning, not in a shipping afterthought. Documentation runs on full consular legalisation, because Syria is not a party to the Hague Apostille Convention: an apostille has no effect there and will be rejected, which catches Indian exporters in particular precisely because India has been an apostille member since 2005 and habitually apostilles everything. There is a real competitive asymmetry worth naming here — with a functioning Syrian mission in New Delhi, an Indian supplier has a cleaner legalisation path than a United States supplier, whose Syrian consular services remain suspended. On the harder questions we do not pretend. Sanctions permission is no longer the constraint, but banking execution is: the Central Bank of Syria has reconnected to SWIFT, the first direct commercial transfer since the war went through on 15 June 2025 and the Commercial Bank of Syria was delisted in July 2025, yet correspondent relationships are immature and no reliable public source quantifies letter-of-credit availability or foreign-exchange access for pharmaceutical importers, so expect advance payment, cash against documents or third-country intermediation and verify with your bank. Add the December 2025 redenomination at 100 old pounds to 1 new pound, which requires restating price lists and tender bids, and the government's declared intent to hold medicine prices and unify them across regions. We would rather set out the agent requirement, the three-equivalents cap, the legalisation chain and the payment reality at the first meeting than discover the gap at the point of filing.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Syria?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, producing more than 100 injectable products under ISO Class 5 aseptic conditions and exporting to over 30 countries. For Syria we prepare the CTD dossier to ICH Modules 1–5 with the Syria-specific Module 1 required by Regulatory Decision No. 3/T of 19 February 2025, provide a consular-legalised Certificate of Pharmaceutical Product or Free Sale Certificate together with legalised GMP certificates for both the finished-product plant and the active-substance site plus the manufacturing licence, prepare English outer-carton and inner-label artwork with the bilingual administration brochure the hospital-injectable exemption requires, and hold stability data comfortably exceeding Syria's Zone II condition of 25°C/60% RH. Because a foreign manufacturer cannot register or import in its own name, we work alongside a client's Ministry-licensed drug warehouse or scientific office.
Do sanctions still prevent supplying injectable medicines to Syria in 2026?
No — and the change is more complete than most commentary suggests. Executive Order 14312 of 30 June 2025 revoked the United States Syria sanctions programme with effect from 1 July 2025; the Syrian Sanctions Regulations at 31 C.F.R. part 542 were removed from the Code of Federal Regulations in August 2025; and the Caesar Syria Civilian Protection Act was repealed by section 6211 of the FY2026 National Defense Authorization Act on 18 December 2025, ending the threat of mandatory secondary sanctions on foreign persons. The European Union adopted the legal acts lifting all economic sanctions on 28 May 2025 and restored full application of the EU–Syria Cooperation Agreement on 11 May 2026, renewing only its targeted former-regime measures on 18 May 2026; the United Kingdom revoked its sectoral, trade, financial and energy measures with effect from 25 April 2025. Medicines to Syria are now ordinary commerce rather than a humanitarian exception, and the widely recycled claim that sanctions block medicine imports derives from sources of 2013 to 2020. What remains is targeted: screen counterparties against the US PAARSS designations and the EU and UK lists, which still cover former-regime figures, human-rights abusers, captagon networks and Iran-linked entities. The practical constraint today is banking execution, not permission.
Can an imported injectable be registered in Syria if the molecule is made locally?
Often yes — the rule is a numerical cap, not a category ban. Regulatory Decision No. 3/T of 19 February 2025, Art. 3.2.2(a), allows an application to register an imported medicine only where three locally licensed and marketed equivalents do not exist. An equivalent is defined by matching active substances, strength, pharmaceutical form and route of administration, so a difference in any one of those four means the local product does not count toward the three; the cap can also be exceeded where a strength or pack is being added to an already registered product. For sterile injectables this matters enormously, because Syrian local capacity is concentrated in some presentations and thin in others: a particular vial strength, a lyophilised rather than liquid form, or a specific route often has zero or one local equivalent even where the molecule itself is produced in Syria. Selecting the portfolio at strength-and-presentation level is therefore the core commercial exercise. A separate provision does bar registering a licensor company's own product where a Syrian plant manufactures it under licence from that company, and Decision 5/T of 1 March 2026 carries that rule forward.
Does Syria require Arabic package inserts for injectable products?
Not for hospital-administered injectables and anaesthetics, and this is one of the most commercially useful provisions in the Syrian rules. Decision 3/T requires the package insert to be in Arabic in addition to English, except where the product is an anaesthetic or an injectable administered in hospitals or health centres — in which case English alone suffices, provided a brochure explaining the route of administration is supplied in both Arabic and English, with an undertaking to include it with every shipment. The outer carton and inner label must in any case carry the essential information in English, including trade name, generic name, strength, pharmaceutical form, pack volume for vials and ampoules, route of administration for injectables, expiry date and batch number, plus the marketing authorisation holder's name and address. For a manufacturer of hospital sterile injectables this removes the single largest artwork and translation cost that normally makes small Middle East launch volumes uneconomic — a materially lower barrier than most Arabic-language markets. Note separately that the imported product must be stamped to show it is imported specially for the account of the named licensed warehouse.
How does public procurement for injectables work in Syria, and where is the demand concentrated?
The Ministry of Health publishes its tenders openly at moh.gov.sy/tenders, and the structure of those notices tells you the policy: there are separate categories for local medicines and for non-local medicines and medicines with a single local source — meaning that where local supply is thin, imports are actively solicited. Tenders are run as domestic sealed-envelope competitions, so a foreign manufacturer bids through its licensed Syrian warehouse rather than directly, and governorate health directorates run their own tenders alongside the central ones. A new central buyer, the General Authority for Supply and Provision, was established on 15 March 2026 by Presidential Decree No. 63 of 2026 reporting to the Presidency, and its precise remit over medicines is not yet clear from published sources. Alongside the Ministry channel sit WHO, whose 2026 health emergency appeal for Syria is US$50.70 million including US$30.0 million for case management and therapeutics, plus UNICEF, UNDP, UNOPS, the Global Fund for HIV and tuberculosis, the ICRC and national partners — and a large private market in which 91% of respondents report paying for health services. Demand is most sharply concentrated in oncology, where the Ministry held about 20% of required supply in April 2026, cancer medicines have held customs pre-clearance priority since January 2026, and the Ministry's published oncology-import decision names India among its approved source countries.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments